Related Experiment Video
Updated: Jun 17, 2026
06:30
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
[Retrobulbar triamcinolone injection and glycemic control]
V M Asensio-Sánchez1, A Soto, S Conde
1Hospital General Servicio Castellano-Leonés de Salud, Servicio de Oftalmología, Medina del Campo, Valladolid, España. victor_asensio@orangemail.es
Archivos De La Sociedad Espanola De Oftalmologia
|January 6, 2010
Summary
Retrobulbar triamcinolone acetonide injections temporarily increased blood glucose in both diabetic and non-diabetic patients. Diabetic individuals experienced more severe hyperglycemia following the corticosteroid treatment.
Area of Science:
- Ophthalmology
- Endocrinology
- Pharmacology
Context:
- Corticosteroids, such as triamcinolone acetonide, are used to treat various ocular conditions.
- Retrobulbar injections deliver medication directly into the space behind the eye.
- Glycemic control is a critical aspect of managing diabetes mellitus.
Purpose:
- To investigate the systemic effect of retrobulbar triamcinolone acetonide on glycemic control.
- To compare the impact on blood glucose levels in diabetic versus non-diabetic patients.
Summary:
- A study involving 40 patients (20 diabetic, 20 non-diabetic) received retrobulbar triamcinolone acetonide injections.
- Capillary blood glucose levels were monitored for 7 days post-injection.
- Both groups showed significant increases in blood glucose at days 1 and 4 post-injection, with diabetics exhibiting more severe hyperglycemia.
Impact:
- Retrobulbar triamcinolone acetonide administration can lead to transient elevations in blood glucose.
- Diabetic patients may be at higher risk for significant hyperglycemia after this procedure.
- This finding is crucial for ophthalmologists and endocrinologists managing patients receiving retrobulbar corticosteroid therapy.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...